Updated: After Phase 3 obesity success, Hengrui plans China approval filing for Kailera-partnered drug

Elizabeth Cairns

Senior biopharma journalist

Jiangsu Hengrui Pharmaceuticals’ injected GLP-1/GIP agonist helped obese patients in a China-based trial lose around 18% of their weight after around 11 months’ treatment, Hengrui …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Updated: After Phase 3 obesity success, Hengrui plans China approval filing for Kailera-partnered drug

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

The Trump administration disbanded a newborn screening panel. Advocates now face a harder path

Merck's PD-1xVEGF partner LaNova gets snapped up for $951M

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

Otsuka buys immunology drugs; JCR, Acumen team up on Alzheimer’s program

FDA employees let go in April receive final termination notices

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA

Up­dat­ed: Af­ter Phase 3 obe­si­ty suc­cess, Hen­grui plans Chi­na ap­proval fil­ing for Kail­era-part­nered drug

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

more like this

The Trump ad­min­is­tra­tion dis­band­ed a new­born screen­ing pan­el. Ad­vo­cates now face a hard­er path

Mer­ck­'s PD-1xVEGF part­ner LaNo­va gets snapped up for $951M

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Ot­su­ka buys im­munol­o­gy drugs; JCR, Acu­men team up on Alzheimer’s pro­gram

FDA em­ploy­ees let go in April re­ceive fi­nal ter­mi­na­tion no­tices

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

Updated: After Phase 3 obesity success, Hengrui plans China approval filing for Kailera-partnered drug

The Trump administration disbanded a newborn screening panel. Advocates now face a harder path

Merck's PD-1xVEGF partner LaNova gets snapped up for $951M

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

Otsuka buys immunology drugs; JCR, Acumen team up on Alzheimer’s program

FDA employees let go in April receive final termination notices

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA